Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00010205 · ClinicalTrials.gov registry record · Phase 1

Benzoylphenylurea in Treating Patients With Advanced Cancer

A Phase 1 study, sponsored by National Cancer Institute (NCI).

Terminated
Registry status
Phase 1
Development phase
30
Enrollment target

NCT00010205: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).

NCT00010205 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00010205, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).

TERMINATED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

This phase I trial is studying the side effects and best dose of benzoylphenylurea in treating patients with advanced cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Interventions

  • OTHER pharmacological study
  • DRUG benzoylphenylurea

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2000-12
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00010205

The ClinicalTrials.gov registry entry for NCT00010205 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.

NCT00010205 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00010205 about?

NCT00010205 is a clinical study titled "Benzoylphenylurea in Treating Patients With Advanced Cancer". This phase I trial is studying the side effects and best dose of benzoylphenylurea in treating patients with advanced cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

What is the current status of trial NCT00010205?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2000-12.

What interventions are being tested in trial NCT00010205?

The interventions under investigation include: pharmacological study (OTHER), benzoylphenylurea (DRUG).

Who is sponsoring clinical trial NCT00010205?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.